Fig. 2From: A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumorsPharmacokinetics of FGF401 and blood pharmacodynamics in patients treated with FGF401 as a single agent. A Plasma concentrations of FGF401 over time are shown in a semi-log view for phase 1 cycle 1 day 8 and B phase 2 cycle 2 day 1. C Bile acid precursor C4 and D total bile acid levels increased after treatment reflecting de-repression of bile acids synthesis as a consequence of FGFR4 pathway inhibition. C4 and total bile acid are shown at different days of cycle for the patients with HCC in the 120 mg fasted dose group. C4: 7α-hydroxy-4-cholesten-3-one bile acidBack to article page